
News|Articles|July 1, 2012
Pipeline Preview
Recent FDA action (through June 2012) related to, Darunavir, Prezista, Janssen Therapeutics, Ridaforolimus, Merck, Tafamidis meglumine, Pfizer, mechlorethamine, Ceptaris Therapeutics, AVP-923, Avanir Pharmaceuticals, NKTR-181, Nektar Therapeutics, EDI200, Edimer Pharmaceuticals, Galeterone, TOK-001, Tokai Pharmaceuticals, Butoconazole nitrate 2% vaginal cream, Gynazole-1, Perrigo
Advertisement
Complete response
Priority review
Fast-track designation
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Biosimilars in 2025: A year of firsts
2
Music and painting dual art therapy improves cognitive and social functions of hospitalized schizophrenia patients, study suggests
3
Looking ahead: What the MHE 2025 State of the Industry survey tells us about 2026
4
Low uptake of shingles vaccine despite strong value proposition for older adults
5






















































